Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided where at least one of R2 or R3 is not hydrogen. The compounds of the present invention are N-methyl-D-aspartate (NMDA) receptor antagonists and are useful in treating a variety of conditions present in a mammal that benefit from inhibiting the NMDA receptor.

Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided where at least one of R2 or R3 is not hydrogen. The compounds of the present invention are N-methyl-D-aspartate (NMDA) receptor antagonists and are useful in treating a variety of conditions present in a mammal that benefit from inhibiting the NMDA receptor.

Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: Compounds useful for the treatment of disorders of the serotonin-affected neurological systems are provided which have the following formula: wherein: X is carbon or nitrogen; R1 and R2 are each, independently, hydrogen, halogen, CF3, alkyl, alkoxy, or MeSO24; R3 is hydrogen, halogen, or alkyl; R4 is hydrogen, alkyl, alkylaryl, or aryl; and R5 is hydrogen, halogen, CF3, CN, carbamide, or alkoxy; or pharmaceutically acceptable salts thereof.

Abstract: This invention provides a process for the preparation of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, methanesulfonylamino, acetylamino, halo, cyano, nitro, or when taken together R.sup.1 and R.sup.2 represent a methylenedioxy or ethylenedioxy moiety;or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides compounds having the structure ##STR1## wherein m=0-1; andn=0-1 or a pharmaceutically acceptable salt thereof when m and n=0, that are useful as neuroprotective agents.

Abstract: This invention provides compounds having the structure ##STR1## wherein R is hydrogen, alkyl, alkenyl, alkynyl, --COR.sup.2, phenyl, or phenylalkyl; the dotted line represents an optional double bond;R.sup.1 is hydrogen, --OH, OR.sup.3, or is absent if the optional double bond is present;R.sup.2 and R.sup.3 are each, independently, alkyl, alkenyl, alkynyl, phenyl, or phenylalkyl;R.sup.4 is hydrogen, --OR.sup.5, alkyl, alkenyl, alkynyl, --COR.sup.5, --CO.sub.2 R.sup.5, --CONR.sup.5 R.sup.6, perhaloalkyl, halogen, phenyl, or phenylalkyl;R.sup.5 and R.sup.6 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, phenyl, or phenylalkyl; andn=0-2or a pharmaceutically acceptable salt thereof that are useful as antipsychotic, antidepressant and anxiolytic agents useful in the treatment and relief of the symptoms of these disease states.

Abstract: The compounds ##STR1## where R and R.sup.6 are members independently selected from the group consisting of H, CN, OR.sup.2, NO.sub.2, NR.sup.2 R.sup.3, NR.sup.2 COR.sup.3, NR.sup.2 COOR.sup.3, COR.sup.2, COOR.sup.2, CONR.sup.2 R.sup.3, SR.sup.2, SOR.sup.2, SO.sub.2 R.sup.2, SO.sub.2 NR.sup.2 R.sup.3, alkyl, alkenyl, alkynyl, perhaloalkyl, and a halogen; in which R.sup.2 and R.sup.3 are alkyl, alkenyl, alkynyl, phenyl, or benzyl; R.sup.4 is a member selected from the group consisting of H, alkyl, heteroalkyl, in which the hetero atom is oxygen, sulfur or nitrogen, alkenyl and alkynyl; R.sup.5 is ##STR2## where X is O, S or NR.sup.7 and R.sup.7 is H or alkyl and n is 1, 2, 3, 4, 5, or 6; or a pharmaceutically acceptable salt thereof, are useful anxiolytic/antidepressant agents.

Abstract: This invention relates to compounds useful as anxiolytic agents having the formula: ##STR1## where A is ##STR2## wherein X is O or S;R.sup.1 is selected from H, --CN, --OR.sup.3, --NO.sub.2, --NR.sup.3 R.sup.4, --NR.sup.3 COR.sup.4, --NR.sup.3 COOR.sup.4, --COR.sup.3, --COOR.sup.3, --CONR.sup.3 R.sup.4, --SR.sup.3, --SOR.sup.3, --SO.sub.2 R.sup.3, --SO.sub.2 NR.sup.3 R.sup.4, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, -perhalo-C.sub.1 -C.sub.6 -alkyl, F, Cl, Br, and I;R.sup.2 is selected from H, --COR.sup.3, --COOR.sup.3, --CONR.sup.3 R.sup.4, --CONHR.sup.3, --COCHR.sup.3 R.sup.4, C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 alkenyl, and C.sub.2 -C.sub.6 -alkynyl;R.sup.3 and R.sup.4 are independently selected from C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 alkynyl, benzyl, or phenyl which may be optionally substituted by one to three groups selected from F, Cl, Br, I, --NO.sub.2, --CN, and --C.sub.1 -C.sub.6 alkoxy; or R.sup.3 and R.sup.

Abstract: This invention provides compounds having the structure ##STR1## wherein R is hydrogen, alkyl, alkenyl, alkynyl, --COR.sup.2, phenyl, or phenylalkyl of 7-10 carbon atoms;the dotted line represents an optional double bond;R.sup.1 is hydrogen, --OH, OR.sup.3, or is absent if the optional double bond is present;R.sup.2 and R.sup.3 are each, independently, alkyl, alkenyl, alkynyl, phenyl, or phenylalkyl;R.sup.4 is hydrogen, --OR.sup.5, alkyl, alkenyl, alkynyl, --COR.sup.5, --CO.sub.2 R.sup.5, --CONR.sup.5 R.sup.6, perhaloalkyl, halogen, phenyl, or phenylalkyl;R.sup.5 and R.sup.6 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, phenyl, or phenylalkyl; andn=0-2or a pharmaceutically acceptable salt thereof that are useful as antipsychotic, antidepressant and anxiolytic agents useful in the treatment and relief of the symptoms of these disease states.

Abstract: The compounds ##STR1## where: R and R.sup.6 are members independently selected from the group consisting of H, CN, OR.sup.2, NO.sub.2, NR.sup.2 R.sup.3, NR.sup.2 COR.sup.3, NR.sup.2 COOR.sup.3, COR.sup.2, COOR.sup.2, CONR.sup.2 R.sup.3, SR.sup.2, SOR.sup.2, SO.sub.2 R.sup.2, SO.sub.2 NR.sup.2 R.sup.3, alkyl, alkenyl, alkynyl, perhaloalkyl, and a halogen;in which R.sup.2 and R.sup.3 are alkyl, alkenyl, alkynyl, phenyl, or benzyl;R.sup.4 is a member selected from the group consisting of H, alkyl, heteroalkyl, in which the hetero atom is oxygen, sulfur or nitrogen, alkenyl and alkynyl;R.sup.5 is alkynyl of 2 to 8 carbon atoms or 1-alkynylcycloalkyl in which the alkynyl group contains 2 to 6 carbon atoms and the cycloalkyl group contains 3 to 10 carbon atoms;or a pharmaceutically acceptable salt thereof, are useful anxiolytic/antidepressant agents.

Abstract: The compounds of the formula ##STR1## wherein R is hydrogen, lower alkyl, benzyl or pivaloyloxymethyl;R.sup.1 and R.sup.2 are, independently, hydrogen, lower alkyl, lower alkoxy, trifluoromethyl, trifluoromethoxy, methanesulfonylamino, acetylamino, or halo, or when taken together R.sup.1 and R.sup.2 represent a methylenedioxy grouping;and the pharmacologically acceptable salts thereof are NMDA antagonists useful in the treatment and prevention of central nervous system related pathological conditions resulting from overstimulation by excitatory amino acids.

Abstract: The compounds of the formula: ##STR1## in which Q is the quinoxaline nucleus; m is one of the integers 0, 1 or 2; n is one of the integers 1,2 or 3; or a pharmaceutically acceptable salt, alkyl ester or ##STR2## where R.sup.3 and R.sup.4 are, independently, hydrogen, nitro, halo or methoxy, are NMDA antagonists useful in the treatment and prevention of central nervous system related pathological conditions resulting from overstimulation by excitatory amino acids.